Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 8 of 16

  1. MLN1202 Placebo

    Takeda

    Diabetic Nephropathy

    phase 2 small molecule terminated

    1 trial

  2. MSC

    Shandong University

    Type 2 Diabetes

    phase 2 mab active

    1 trial

  3. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  4. Matching Placebo

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  5. MenSCs transplantation

    The First People's Hospital of Lianyungang

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  6. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  7. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  8. Motivational Interviewing

    Cardiff Oncology

    Diabetes Mellitus

    phase 2 other terminated

    1 trial

  9. NAT-19/GPX

    Dr. Falk Pharma GmbH

    Idiopathic or Diabetic Gastroparesis

    phase 2 small molecule active

    1 trial

  10. NN9388-7700

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  11. NN9388-7864

    NovoThirteen

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  12. NN9490-7678

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  13. NN9500-4656

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  14. NN9541-7841

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  15. NN9662-8160

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  16. Naltrexone hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Obesity

    phase 2 small molecule active

    1 trial

  17. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  18. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  19. ORMD 0801

    ORAMED PHARMACEUTICALS INC.

    Brittle Type I Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  20. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  21. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  22. ORMD-0801 Capsules

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 1

    phase 2 mab completed

    1 trial

  23. ORMD-0801 Dose # 1

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  24. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  25. ORMD-0801 Treatment A

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  26. ORMD-0801 capsules- 2x8mg

    ORAMED PHARMACEUTICALS INC.

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  27. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  28. Omnitram Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  29. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  30. Oshadi Icp

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Insulin-Dependent, 1

    phase 2 small molecule completed

    1 trial

  31. P120142

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  32. PEX168 or placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  33. PRAM9

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  34. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  35. Pear

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome

    phase 2 other completed

    1 trial

  36. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  37. Pioglitazone and azilsartan

    Takeda

    Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  38. Placebo

    IONIS PHARMACEUTICALS INC

    NAFLD

    phase 2 small molecule completed

    1 trial

  39. Placebo

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  40. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  41. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  42. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  43. Pramlintide+Metreleptin

    Takeda

    Obesity

    phase 2 small molecule terminated

    1 trial

  44. Pro insulin peptide

    Cardiff Oncology

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  45. REGN910-3

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  46. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  47. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  48. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.